BOSTON - Drug stocks were mixed in early action Wednesday as shares of Eli Lilly & Co. (LLY 32.95, +0.11, +0.33%) lost ground after the drugmaker said it was pulling the plug on its osteoporosis drug candidate arzoxifene due to disappointing clinical trial results. The NYSE Arca Pharmaceutical Index (DRG 280.34, +3.85, +1.39%) was up nominally at 276.57 and the NYSE Arca Biotechnology Index (BTK 859.95, +18.46, +2.19%) declined 0.6% to 836.58. Shares of Lilly were off 1% at $32.55. The osteoporosis treatment had been in Phase III clinical testing.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
No comments:
Post a Comment